Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
2
Neutral
5
Bullish
7
Bearish
20
Neutral
17
Bullish
9
Bearish
18
Neutral
12
Bullish
2
Discovery themes featuring this stockPharmaceuticals & Biotechnology
Pharmaceuticals
58 Cr
Low Risk
-1.8
32.0
—
—
27.99
6.58
Sales CAGR
Profit CAGR
ROE
ROCE
Vivimed Labs Ltd (VIVIMEDLAB) is currently trading at 6.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vivimed Labs Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Vivimed Labs Ltd has traded between a low of ₹6.58 and a high of ₹27.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vivimed Labs Ltd has a market capitalization of approximately 57.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vivimed Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -1.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 57.54 Cr, Vivimed Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vivimed Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vivimed Labs Ltd is -1.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Financial Results
Board of Vivimed Labs approved and authorised submission of unaudited standalone and consolidated financial results for the quarter and nine months ended 31 Dec 2025 and noted auditors' limited review report (meeting on 13 Mar 2026).
Board Meeting Notice
Vivimed Labs intimes a Board meeting on 13-Mar-2026 at Hyderabad to consider and approve unaudited standalone & consolidated financial results for the quarter and nine months ended 31-Dec-2025 and other items.
Board Meeting Intimation
Vivimed Labs has scheduled a Board meeting on 13‑Mar‑2026 in Hyderabad to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended 31‑Dec‑2025 and other items.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
82.35 | 62 Cr | 16.77 | 1.43 | 0.00 | 12.65 | 11.11 | 2.27 | |
89.94 | 61 Cr | 3.46 | 9.44 | 0.00 | 7.28 | 7.84 | 40.10 | |
32.80 | 59 Cr | 9.91 | 1.07 | 0.00 | 1.95 | 4.14 | 1.16 | |
6.95 | 58 Cr | -1.85 | 0.00 | 0.00 | 50.81 | -2.49 | -3.78 | |
29.88 | 57 Cr | -5.65 | 1.30 | 0.00 | -117.41 | -22.41 | -11.20 | |
33.01 | 55 Cr | 5.27 | 0.92 | 0.00 | 13.52 | 17.90 | 12.26 | |
0.52 | 52 Cr | -29.60 | 0.47 | 0.00 | -0.10 | 0.05 | -0.90 | |
| Median: 7 Co. | 32.80 | 58 Cr | 3.46 | 1.07 | 0.00 | 7.28 | 4.14 | 1.16 |
